When was Noxopharm founded?

Noxopharm was founded in 2015 and raised its 1st funding round 3 years after it was founded.

Where is Noxopharm located?

Noxopharm is headquartered in Melbourne, Australia.

How many employees does Noxopharm have?

As of Jul 01, 2024, the latest employee count at Noxopharm is 21.

Is Noxopharm a funded company?

Noxopharm is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Mar 22, 2018.

When was the latest funding round of Noxopharm?

Noxopharm's latest funding was a $***** Grant (prize money) round on Apr 04, 2024, with participation from 0 investor.

Where does Noxopharm rank among its competitors?

Noxopharm ranks 865th amongst 3192 active competitors, of which 1091 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Noxopharm?

Noxopharm's top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Noxopharm - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drugs for the treatment of cancer and septic shock. Its lead product Veyonda is to work with chemotherapy and radiotherapy against cancer. The other drugs include DARRT-1, LuPIN an enhancing radiotherapy program to treat metastatic Castrate Resistant Prostate Cancer (mCRPC), and CEP-1 chemotherapy enhancing program for the treatment of metastatic solid tumors (breast, prostate, lung, ovarian, and head & neck).

Website: noxopharm.com
Social
Email ID: *****@noxopharm.com
Phone Number: +61 **********

Key Metrics

Founded Year

2015

Location

Melbourne, Australia

Stage

Public

Latest Funding Round

Grant (prize money), Apr 04, 2024, $*****

Investors

The Australian health system & 1 more

Ranked

865^th among 3192 active competitors

Employee Count

21 as on Jul 01, 2024

Similar Companies

Jazz Pharmaceuticals & 2957 more

Exit Details

Public

View Noxopharm's full profile

Noxopharm got listed on Aug 09, 2016.

Click here to take a look at Noxopharm's IPO in detail

Noxopharm has raised funding over 4 rounds. Its first funding round was on Mar 22, 2018. Noxopharm has 2 institutional investors.

Here is the list of recent funding rounds of Noxopharm:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 04, 2024	9874957	Grant (prize money)	5181629	8554134	3473561	3350985
Jun 27, 2022	6407350	Grant (prize money)	6414763	8140442	6351480	Victorian Government
Nov 15, 2021	3835928	Grant (prize money)	3766435	2147633	4497532	The Australian health system

Access funding benchmarks and valuations. Sign up today!

View details of Noxopharm's funding rounds and investors

The founders of Noxopharm is Graham Kelly.

Here are the details of Noxopharm's key team members:

Graham Kelly: Founder, Noxopharm Limited of Noxopharm.

View details of Noxopharm's Founder profiles and Board Members

Noxopharm's employee count trend

Noxopharm has 21 employees as of Jul 24. Here is Noxopharm's employee count trend over the years:

Uncover Noxopharm's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Noxopharm include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Noxopharm, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
6th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Tamburi Investment Partners, Vivo Capital ... & 4 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
8th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
865th	Noxopharm 2015, Melbourne (Australia), Public	Developer of drugs for the treatment of cancer and septic shock	-	The Australian health system, Victorian Government	44/100